Tech Company Financing Transactions

Cerulean Pharma Funding Round

Bessemer Venture Partners, Lilly Ventures and Lux Capital joined a $15 million Series D venture round for Cerulean Pharma. The round closed on 12/15/2011.

Transaction Overview

Company Name
Cerulean Pharma
Announced On
12/15/2011
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series D
Investors

Bessemer Venture Partners (Stephen Kraus)

Lilly Ventures (Steven Hall)

Lux Capital (Robert Paull)

Polaris Partners (Alan Crane)

Venrock (Bryan Roberts)

Proceeds Purpose
The financing proceeds will be used to complete a randomized Phase 2 trial of CRLX101 in non-small cell lung cancer, and to support several investigator-sponsored CRLX101 Phase 2 trials in additional indications at leading academic medical centers. Additionally, Cerulean's docetaxel nanopharmaceutical candidate will be advanced into clinical trials, and the Company will aggressively pursue other platform expansion opportunities, including the delivery of RNA-based therapeutics.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
840 Memorial Dr.
Cambridge, MA 02139
USA
Phone
(617) 551-9600
Website
www.ceruleanrx.com
Email Address
[email protected]
Overview
Cerulean Pharma develops nanotechnology-based therapeutics for treating oncology, cardiovascular, autoimmune and inflammatory diseases.
Profile
Cerulean Pharma LinkedIn Company Profile
Social Media
Cerulean Pharma Company Twitter Account
Company News
Cerulean Pharma News
Facebook
Cerulean Pharma on Facebook
YouTube
Cerulean Pharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Paul Friedman
  Paul Friedman LinkedIn Profile  Paul Friedman Twitter Account  Paul Friedman News  Paul Friedman on Facebook
VP - Bus. Development
Christopher Guiffre
  Christopher Guiffre LinkedIn Profile  Christopher Guiffre Twitter Account  Christopher Guiffre News  Christopher Guiffre on Facebook
VP - Finance
Karen Roberts
  Karen Roberts LinkedIn Profile  Karen Roberts Twitter Account  Karen Roberts News  Karen Roberts on Facebook
VP - Manufacturing
Marc Wolfgang
  Marc Wolfgang LinkedIn Profile  Marc Wolfgang Twitter Account  Marc Wolfgang News  Marc Wolfgang on Facebook
VP - R & D
Scott Eliasof
  Scott Eliasof LinkedIn Profile  Scott Eliasof Twitter Account  Scott Eliasof News  Scott Eliasof on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/15/2011: MicroVentures venture capital transaction
Next: 12/15/2011: Ember Therapeutics venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.